Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Abstract Background HER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of new therapeutics has led to the approval of pertuzumab combined with trastuzumab and a taxane in first-line, and t...

Full description

Bibliographic Details
Main Authors: Giulia Bon, Laura Pizzuti, Valentina Laquintana, Rossella Loria, Manuela Porru, Caterina Marchiò, Eriseld Krasniqi, Maddalena Barba, Marcello Maugeri-Saccà, Teresa Gamucci, Rossana Berardi, Lorenzo Livi, Corrado Ficorella, Clara Natoli, Enrico Cortesi, Daniele Generali, Nicla La Verde, Alessandra Cassano, Emilio Bria, Luca Moscetti, Andrea Michelotti, Vincenzo Adamo, Claudio Zamagni, Giuseppe Tonini, Giacomo Barchiesi, Marco Mazzotta, Daniele Marinelli, Silverio Tomao, Paolo Marchetti, Maria Rosaria Valerio, Rosanna Mirabelli, Antonio Russo, Maria Agnese Fabbri, Nicola D’Ostilio, Enzo Veltri, Domenico Corsi, Ornella Garrone, Ida Paris, Giuseppina Sarobba, Francesco Giotta, Carlo Garufi, Marina Cazzaniga, Pietro Del Medico, Mario Roselli, Giuseppe Sanguineti, Isabella Sperduti, Anna Sapino, Ruggero De Maria, Carlo Leonetti, Angelo Di Leo, Gennaro Ciliberto, Rita Falcioni, Patrizia Vici
Format: Article
Language:English
Published: BMC 2020-12-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
HER2+ breast cancer
Trastuzumab/pertuzumab blockade
T-DM1 efficacy
Online Access:https://doi.org/10.1186/s13046-020-01797-3

Internet

https://doi.org/10.1186/s13046-020-01797-3

Similar Items